Detail akcie Alnylam Pharm online

Business Summary: Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Alnylam Pharmaceuticals, Inc. revenues increased 19% to $1.37B. Net loss increased 49% to $123.8M. Revenues reflect AMVUTTRA segment increase of 89% to $801.9M, Other segment increase from $36.7M to $108.2M, United States segment increase of 70% to $726M, Europe segment increase of 19% to $303.2M. Higher net loss reflects General and administrative - Balancing v increase of 54% to $315.3M (expense).